



HUMAN BEHAVIOR INSTITUTE

Full Service Behavioral Health

6039 Eldora St. Ste. H, Las Vegas, NV 89146

Phone: (702) 248-8866

Fax: (702) 248-0183

DATE: 03/17/2025

Dear Members of the Nevada State Medicaid Board,

We are writing to advocate for the inclusion of Caplyta (lumateperone) in the Nevada Medicaid formulary for the treatment of Bipolar I and II depression and schizophrenia. As we know, mental health challenges are among the most pressing issues facing our communities today, and having access to effective treatment options is vital for the well-being of those affected.

Caplyta has shown significant promise in clinical trials, demonstrating efficacy in alleviating symptoms of both bipolar depression and schizophrenia. As a novel, oral antipsychotic medication, it works through a unique mechanism that is not only effective but also generally well-tolerated by patients. This is particularly important given the diverse needs and responses of our patients suffering from these complex mental health conditions.

For many individuals, bipolar disorder and schizophrenia are not just diagnoses; they are life-altering conditions that can lead to debilitating symptoms, resulting in lost opportunities, strained relationships, and increased reliance on healthcare resources. The inclusion of Caplyta in the Medicaid formulary could provide a much-needed lifeline for many patients who have struggled to find effective treatments that suit their individual needs.



Access to Caplyta could lead to significant improvements in overall quality of life for patients, reducing the burden on families and communities and potentially decreasing the need for more intensive health services. Furthermore, by offering a broader range of treatment options, Nevada Medicaid can empower healthcare providers to tailor their treatment plans to better meet the unique needs of their patients.

We urge you to consider the positive impact that adding Caplyta to the formulary could have on the mental health landscape in Nevada. Expanding access to this essential medication will not only help individuals manage their conditions more effectively but will also foster a more supportive environment for those navigating the challenges of mental illness.

Thank you for your time and consideration of this important matter. We hope you will advocate for the inclusion of Caplyta in the Medicaid formulary, as it represents a crucial opportunity to enhance the lives of many Nevadans living with mental health disorders.

Sincerely,



STEADFAST BEHAVIORAL CLINIC

ESTRA HEALTHCARE SERVICES

Psychiatry/Mental Health Clinic

3170 W SAHARA AVE. SUITE 011. LAS VEGAS NEVADA. 89102

CALL: 702 478 6983

FAX: 702 478 7109

March 19, 2025

To whom this may concern:

We are writing to recommend CAPLYTA® (lumateperone) based on our patient's significant experience with the medication. As a Clinician/Provider at Steadfast Behavioral Clinic, we have had the privilege of observing the efficacy, tolerability, and safety profile of CAPLYTA® in adults for the treatment of depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression).

Our patients that's has been under our care during which CAPLYTA® has demonstrated remarkable effectiveness in managing their symptoms. Notably, patients reported a noticeable reduction in their symptoms, leading to improved overall quality of life and functionality.

In terms of tolerability, CAPLYTA® has proven to be well-tolerated. They experienced minimal adverse effects, which were manageable and did not interfere significantly with treatment adherence. This aspect is crucial in ensuring compliance and long-term therapeutic success.


Regarding safety, we have closely monitored patient's health parameters throughout the treatment duration. We are pleased to report that CAPLYTA® has exhibited a favorable safety profile, with no serious adverse events or concerns noted during our regular assessments.

Based on our patient's positive response to CAPLYTA®, We confidently recommend this medication for consideration in the management of depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression) in other patients. Its efficacy, combined with favorable tolerability and safety, positions CAPLYTA® as a valuable option in our therapeutic armamentarium.

Please feel free to contact our clinic if you require any further information or clarification in regard to patients experience with CAPLYTA®. Thank you for considering this recommendation.

Sincerely,

BRENDA ORTIZ, APR



STEADFAST BEHAVIORAL CLINIC

ESTRA HEALTHCARE SERVICES

Psychiatry/Mental Health Clinic

3170 W SAHARA AVE. SUITE D11. LAS VEGAS NEVADA. 8 9102 CALL: 702 478 6983 FAX: 702 478 7109

March 18, 2025

To whom this may concern:

We are writing to recommend CAPLYTA®(lumeperone) based on our patient's significant experience with the medication. As a Clinician/Provider at Steadfast Behavioral Clinic, we have had the privilege of observing the efficacy, tolerability, and safety profile of CAPLYTA® in adults for the treatment of depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression).

Our patients that's has been under our care during which CAPLYTA® has demonstrated remarkable effectiveness in managing their symptoms. Notably, patients reported a noticeable reduction in their symptoms, leading to improved overall quality of life and functionality.

In terms of tolerability, CAPLYTA® has proven to be well-tolerated. They experienced minimal adverse effects, which were manageable and did not interfere significantly with treatment adherence. This aspect is crucial in ensuring compliance and long-term therapeutic success.

Regarding safety, we have closely monitored patient's health parameters throughout the treatment duration. We are pleased to report that CAPLYTA® has exhibited a favorable safety profile, with no serious adverse events or concerns noted during our regular assessments.

Based on our patient's positive response to CAPLYTA®, We confidently recommend this medication for consideration in the management of depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression) in other patients. Its efficacy, combined with favorable tolerability and safety, positions CAPLYTA® as a valuable option in our therapeutic armamentarium,

Please feel free to contact our clinic if you require any further information or clarification in regard to patients experience with CAPLYTA®. Thank you for considering this recommendation.

Sincerely,

KEVIN ENCINAREAL, APRN,PMHNP-BC

 APRN, PMHNP, BC

STEADFAST BEHAVIORAL CLINIC

ESTRA HEALTHCARE SERVICES

Psychiatry/Mental Health Clinic

3170 W SAHARA AVE. SUITE D11. LAS VEGAS NEVADA. 89102

CALL: 702 478 6983

FAX: 702 478 7109

March 17, 2025

To whom this may concern:

We are writing to recommend CAPLYTA® (lumateperone) based on our patient's significant experience with the medication. As a Clinician/Provider at Steadfast Behavioral Clinic, we have had the privilege of observing the efficacy, tolerability, and safety profile of CAPLYTA® in adults for the treatment of depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression).

Our patients that's has been under our care during which CAPLYTA® has demonstrated remarkable effectiveness in managing their symptoms. Notably, patients reported a noticeable reduction in their symptoms, leading to improved overall quality of life and functionality.

In terms of tolerability, CAPLYTA® has proven to be well-tolerated. They experienced minimal adverse effects, which were manageable and did not interfere significantly with treatment adherence. This aspect is crucial in ensuring compliance and long-term therapeutic success.

Regarding safety, we have closely monitored patient's health parameters throughout the treatment duration. We are pleased to report that CAPLYTA® has exhibited a favorable safety profile, with no serious adverse events or concerns noted during our regular assessments.

Based on our patient's positive response to CAPLYTA®, We confidently recommend this medication for consideration in the management of depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression) in other patients. Its efficacy, combined with favorable tolerability and safety, positions CAPLYTA® as a valuable option in our therapeutic armamentarium.

Please feel free to contact our clinic if you require any further information or clarification in regard to patients' experience with CAPLYTA®. Thank you for considering this recommendation.

Sincerely,



CHARLENE NARDO, APRN, PMHNP-BC